|
Adenocarcinoma
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Ion AmpliSeq Cancer Panel detected 9 potentially actionable variants in 29 adenocarcinomas that were wild type by the 8-gene panel testing (9 of 29, 31.0%) in the following genes: ERBB2 (3 of 29, 10.3%), STK11 (2 of 29, 6.8%), PTEN (2 of 29, 6.8%), FBXW7 (1 of 29, 3.4%), and BRAF G469A (1 of 29, 3.4%).
|
29219616 |
2018 |
|
Aortic Aneurysm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In an angiotensin II (Ang II)-induced mouse aortic aneurysm (AA) model, PTENP1 overexpression potentiated aortic SMC apoptosis, exacerbated aneurysm formation.
|
31235554 |
2019 |
|
Aortic aneurysm without mention of rupture NOS
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In an angiotensin II (Ang II)-induced mouse aortic aneurysm (AA) model, PTENP1 overexpression potentiated aortic SMC apoptosis, exacerbated aneurysm formation.
|
31235554 |
2019 |
|
Autistic Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Exome sequencing of the family also identified a rare inherited variant predicted to disrupt splicing of TPTE / PTEN2, a PTEN homologue, which may likewise contribute to both macrocephaly and autism risk.
|
26076356 |
2015 |
|
Bladder Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Normal cells secreted exosomal PTENP1 and transmitted it to BC cells, thus inhibiting the biological malignant behavior of BC cells by increasing cell apoptosis and reducing the ability to invade and migrate (P < 0.05).
|
30285771 |
2018 |
|
Breast Carcinoma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Moreover, alteration of PTENP1 affects BC cell proliferation, invasion, tumorigenesis and chemoresistance to adriamycin (ADR).
|
31196157 |
2019 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Enhanced PTENP1 could inhibit BC cell growth, metastasis and tumourigenicity by inhibiting miR-19b and facilitating PTEN in BC, thereby may represent a novel target for diagnosis and treatment of BC.
|
28731027 |
2017 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
LncRNA PTENP1 can inhibit the proliferation and migration of breast cancer cells via the AKT and MAPK signaling pathways.
|
29085464 |
2017 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
PTENP1 performed a negative role in the development of BC via downregulating miR-19 probably through the PTEN/PI3K/Akt pathway.
|
29212574 |
2018 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Further studies are needed to evaluate the impact of PTEN/PTENP1/miRNA interactions on tumorigenesis regulation in EMCA.
|
22005521 |
2012 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Exosomes derived from normal cells transfer PTENP1 to BC cells, which reduce the progression of BC both in vitro and in vivo and suggest that exosomal PTENP1 participates in normal-cell-to-bladder-cell communication during the carcinogenesis of BC.
|
30285771 |
2018 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
PTENP1, a long noncoding RNA, has previously been reported to be involved in tumorigenesis and cancer progression.
|
30229832 |
2018 |
|
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
The PTENP1 Pseudogene, Unlike the PTEN Gene, Is Methylated in Normal Endometrium, As Well As in Endometrial Hyperplasias and Carcinomas in Middle-Aged and Elderly Females.
|
29713518 |
2019 |
|
Carcinoma of bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Normal cells secreted exosomal PTENP1 and transmitted it to BC cells, thus inhibiting the biological malignant behavior of BC cells by increasing cell apoptosis and reducing the ability to invade and migrate (P < 0.05).
|
30285771 |
2018 |
|
Childhood Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Long non-coding RNA phosphatase and tensin homolog pseudogene 1 suppresses osteosarcoma cell growth via the phosphoinositide 3-kinase/protein kinase B signaling pathway.
|
29805503 |
2018 |
|
Colorectal Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Rare mutations not typically associated with CRC included AKT1 (4), AKT2 (1), IDH1 (1), KIT (1), MAP2K1 (1), PTEN (2), and GNAS (6).
|
25683705 |
2015 |
|
Cone monochromatism
|
0.010 |
Biomarker
|
disease |
BEFREE |
Selective knockdown of PTENP1, the most increased lncRNA after implanted BCM treatment in the HEECs, compromised the spheroid adhesion (P < 0.001).
|
31504217 |
2020 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that PTENP1 functions as a competing endogenous RNA (ceRNA) in ccRCC to suppress cancer progression.
|
25249556 |
2014 |
|
Dissection of aorta
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PCR analysis and Western blot assays respectively showed that both PTENP1 and PTEN were up-regulated in human aortic dissection (AD) samples.
|
31235554 |
2019 |
|
ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME 1
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the expression of PTEN/PTENP1 and miR-200c also showed a converse relationship in EEC cell lines.
|
30584245 |
2018 |
|
Endometrial Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we sought to determine whether PTENP1 is expressed in endometrial cancer (EMCA) cell lines and primary tumors along with the microRNAs (miRNAs) that are predicted to regulate PTEN and PTENP1 transcript levels.
|
22005521 |
2012 |
|
Endometrial Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Estrogen affects the negative feedback loop of PTENP1-miR200c to inhibit PTEN expression in the development of endometrioid endometrial carcinoma.
|
30584245 |
2018 |
|
Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The psiPTEN expression was complementary to PTEN mutation, for 14 of 18 glioblastomas showed either PTEN mutation or psiPTEN expression and only one case showed both PTEN mutation and psiPTEN expression (P<0.046), suggesting a pathological role of psiPTEN expression as an alternative to PTEN mutation in glioblastomas.
|
10980610 |
2000 |
|
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our study investigated the function of PTENP1 in glioma and provided new insights for treating that malignancy.
|
30613153 |
2019 |
|
HER2-positive carcinoma of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A target prediction analysis coupled with in vitro and in vivo validations revealed that miR-21 levels inversely correlated with the expression of PTEN (rs = -0.502; p = 0.005) and PDCD4 (rs = -0.426; p = 0.019), which differentially influenced the drug sensitivity of HER2-positive breast cancer cells.
|
26452030 |
2015 |